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Background: The safety and efﬁcacy of upfront sunitinib, before nephrectomy in metastatic clear cell renal cancer
(mCRC), has not been prospectively evaluated.
Methods: Two prospective single-arm phase II studies investigated either two cycles (study A: n = 19) or three cycles
(study B: n = 33) of sunitinib before nephrectomy in mCRC.
Results: Overall, 38 of 52 (73%) of patients obtained clinical beneﬁt (by RECIST) before surgery. The partial response
rate of the primary tumour was 6% [median reduction in longest diameter of 12% (range 8%235%)]. No patients
became ineligible due to local progression of disease. A nephrectomy was carried out in 37 (71%) of patients. Necrosis
(>50%) was a prominent feature at nephrectomy in 49%. Surgical complications (Clavien–Dindo classiﬁcation)
occurred in 10 (27%) patients, including one death (3%). The median blood loss and surgical time were 725 (90–4200)
ml and 189 (70–420) min, respectively. The median progression-free survival was 8 months (95% conﬁdence interval
6–15 months). A comparison of two versus three pre-surgery cycles showed no signiﬁcant difference in terms of
surgical complications or efﬁcacy.
Conclusions: Nephrectomy after upfront sunitinib can be carried out safely. It obtains control of disease.
Randomised studies are required to address if this approach is beneﬁcial.
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introduction
The introduction of targeted antiangiogenic agents has
revolutionised the treatment of metastatic clear cell renal cancer
(mCRC) [1–7]. Sunitinib, a multitargeted tyrosine kinase
inhibitor (TKI), is established as ﬁrst-line therapy in metastatic
disease [2].
The role of cytoreductive nephrectomy in mCRC in the era
of targeted therapy is not well established. The randomised data
supporting its use comes from the pre-targeted therapy era,
when less effective immune therapy was standard care [8, 9].
The vast majority of patients in the randomised sunitinib
studies have had a nephrectomy before therapy [10].
The timing of this nephrectomy is an area of great interest.
Theoretically treating with upfront sunitinib before
nephrectomy has advantages in mCRC. These include
commencing systemic therapy more quickly to obtain disease
control and down staging the primary tumour facilitating
surgery [11]. It is also possible that this upfront approach
selects out patients with rapidly progressive disease who may
not beneﬁt most from nephrectomy [12]. However, there are
potential risks associated with upfront targeted therapy, such as
delayed wound healing, local progression of disease before
surgery and tumour regrowth in the interval off sunitinib
during the nephrectomy [11–15]. For these reasons, the
European Organisation for Research and Treatment of Cancer
30073 randomised phase III study, comparing upfront
sunitinib followed by nephrectomy against nephrectomy
followed sunitinib will open in 2010. However, knowledge of
the safety and efﬁcacy of upfront sunitinib therapy before
nephrectomy in prospective series is essential.
In this manuscript, two single-arm phase II prospective
studies, evaluating upfront sunitinib before nephrectomy, are
assessed together and individually to address these issues. The
two studies were almost identical in terms of patient’s
characteristics, design and end points. However, the number of
cycles of upfront sunitinib given before nephrectomy (two vs
three) and the treatment free interval before nephrectomy (1 vs
14 days) differ. This allows assessment of the optimal number
of cycles before surgery and optimal treatment-free interval.
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study design and patients selection
This manuscript combines two open single-arm prospective studies with
similar designs and end points. The studies, which are now closed, were
combined to obtain more powerful and meaningful safety and efﬁcacy data
in this setting before the prospective randomised clinical trial commencing.
Both studies consisted of previously untreated patients with newly
diagnosed biopsy proven mCRC. Only patients with either intermediate-
risk or poor-risk [Memorial Sloan Kettering Cancer Center (MSKCC)
criteria [16]] disease were included in both studies. None of the patients
had previously received any systemic therapy. Patients were given either two
cycles (study A) or three cycles (study B) of sunitinib (50 mg p.o. od, 4
weeks on 2 weeks off) before a planned nephrectomy. After the
nephrectomy, patients continued on sunitinib until progression. Imaging
with computed tomography scan of the chest and abdomen was carried out
before therapy and before and after surgery in both studies. Subsequent
imaging was carried out on a 12 weekly basis after nephrectomy. Analysis of
both studies was carried out centrally for all aspects including radiology [Dr
Katani (RECIST v1.1)]. Those patients who did not have a nephrectomy,
for either surgical reasons or through patient choice, continued on
sunitinib until progression. Patients with progression of metastatic disease
before nephrectomy did not undergo surgery. Analysis of both studies took
place centrally in December 2009. Descriptive statistics were used to
compare patients and groups. The overall survival and progression-free
survival (PFS) were analysed using Kaplan–Meier plots. Univariate and
multivariate analysis was carried out to identify prognostic factors
associated with a poor outcome.
study A: design and patients characteristics
From June 2007 to August 2009, 19 patients were enrolled from The
Netherlands Cancer Institute. Patients with untreated biopsy proven clear
cell renal cancer received two cycles of sunitinib therapy before
a nephrectomy, which took place 24 hr after the last dose of sunitinib. A
further minimum 21-day enforced treatment break occurred after
nephrectomy, before restarting sunitinib therapy.
study B: design and patients characteristics
From January 2008 to August 2009, 33 patients were enrolled from two
treatment centres in the UK. Patients received three cycles of sunitinib
before planned nephrectomy. Surgery took place 14 days after the last dose
of sunitinib therapy (day 28 cycle 3). Sunitinib was planned to start
a minimum of 14 days after the surgery.
trial statistics and ethical considerations
Both studies were followed by a Simon’s 2-stage design. The primary end
point of study A was response rate to the primary tumour, while in study B,
it was clinical beneﬁt to the primary tumour. Study A did not reach the 2nd
stage due to the low response rate, while study B progressed to the 2nd stage
and met its primary end point of clinical beneﬁt. These data are given in
Table 2. Both studies were reviewed and approved by an established
independent national ethical committee and were carried out according to
good clinical practice guidelines.
results
patients characteristics and outcome
A total of 52 patients with clear cell tumours were enrolled into
these two studies and started sunitinib therapy (19 from study
A and 33 from study B) (Table 1 and Figure 1). The
characteristics of these patients is summarised in Table 1.
Forty-one (77%) were male and the median age was 60.5 years
(range 37–78). Seventeen (33%) had MSKCC poor-risk disease
and 35 (67%) had intermediate-risk disease. Study B included
more patients with poor-risk disease [16 (50%) versus 1 (5%)].
Median longest diameter of the primary tumour before
treatment was 9.45 cm (range 4.2–23.2 cm). The median PFS
for the cohort was 8 months (95% conﬁdence interval 5–15)
and the median overall survival has not been reached.
Univariate and multivariate analysis showed that the number of
metastatic sites was the only factor associated with a shorter
PFS (P < 0.05). Other factors such as study design (A versus B),
MSKCC prognostic group (intermediate versus poor), gender
and age were not signiﬁcant (P > 0.05 for each).
radiological outcomes with upfront sunitinib before
surgery
All but two of the patients were assessable radioligically before
surgery (Table 2 and Figure 2A and B). One of these patients
died of pneumonia within 4 weeks of starting sunitinib, while
the other patient stopped therapy and switched to another TKI
(sorafenib) during cycle 1 of sunitinib. Upfront therapy was
associated with a median reduction of the longest diameter of
the primary tumour of 12% (range 8%235%). A partial
response by RECIST criteria to the primary tumour occurred in
three patients (6%). No patients had progression of the renal
tumour by RECIST or became ineligible. The number of cycles
did not have a signiﬁcant effect on the reduction of the primary
tumour (Figure 2A).
Overall, a clinical beneﬁt (by RECIST) occurred in 38 (73%)
of patients (79% in study A and 70% in study B). Five (10%)
patients achieved an overall partial response, while 12 (24%)
had progression of disease at the time of surgery. The partial
response rate for the metastatic sites was higher (27%) than
that seen in the primary tumour (6%) (P < 0.05) (Figure 2A
and B). The number of cycles of therapy before surgery and
MSKCC risk group did not have a signiﬁcant effect on the
response rate (P > 0.05).
surgical outcomes and complications
Thirty-seven (70%) of the 53 patients had a radical nephrectomy
(Table 3). The reasons for not undergoing a nephrectomy were
progression of systemic disease (n = 9), patients choice (n = 3)
and being unﬁt for surgery at the time of nephrectomy (n = 2).
The two further patients who were not assessable for
radiological end points (described above) did not have surgery
(early death due to infection and switched therapy).
The median blood loss was 725 ml (range 90–4200 ml), while
the duration of surgery and median hospital stay was 189 min
(range 70–420 min) and 8 days (range 4–36 days), respectively.
Surgical complications occurred in 10 (27%) patients,
including delayed wound healing (n = 5) (16%) (Clavien I),
post-operative oedema (1) (Clavien I), bleeding requiring
surgical reintervention (1) (Clavien IIIb), renal failure requiring
dialysis (1) (Clavien IVa) and post-operative hypotension
requiring ICU admission (1) (Clavien IVa). There was a post-
operative death due to respiratory failure (Clavien V). A
signiﬁcant increase in the plasma creatinine after surgery from
78 lmol/l (57–135) to 109 lmol/l (69–221) occurred in this
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complications seen with either 1 or 14 days off treatment before
surgery showed no signiﬁcant differences.
Clear cell renal cancer was conﬁrmed in 100% of patients at
surgery. The majority of tumours were grade 2 (43%) or 3
(46%). Forty-nine percent of tumours contained >50% necrosis
at the time of surgery. Tissue ﬁbrosis was a prominent
feature in 13 (62%) cases in study B, this did not occur in
study A.
sunitinib therapy post-operative
The median time from nephrectomy to restarting sunitinib was
21 days (range 14–82 days) and median duration off therapy,
including pretreatment break was 28 days (range 22–96 days)
(Table 3).
A signiﬁcant proportion of patients had progression of
disease by RECIST criteria 8/32 (25%) after the surgery-related
treatment break. Reintroduction of sunitinib therapy resulted
in stabilisation of disease in 71% (5/7) of these patients when
compared with the metastatic sites of the last staging before
surgery.
At progression, three patients received second-line therapy [one
with sorafenib and two with mammalian target of rapamycin
(mTOR) inhibitors]. This was largely due to the lack of
availability of second-line therapy during this study period.
sunitinib toxicity before planned nephrectomy
Grade 3 or more toxicity occurred in 16 (30%) patients before
nephrectomy and 11 (21%) had a dose reduction during this
period of time. Toxicity did not delay scheduled surgery in any
case. The most commonly encountered toxicity were mucositis
(15%), hand and foot syndrome (11%), fatigue (9%),
hypertension (6%) and diarrhoea (6%). These results are in line
with previous results with sunitinib [2].
discussion
To our knowledge, these are the ﬁrst studies to prospectively
report on the safety and efﬁcacy of upfront sunitinib in
Table 1. Patients demographics and characteristics at diagnosis
Combined data Study A: 2 sunitinib cycles Study B: 3 sunitinib cycles
Number of patients 52 19 (37%) 33 (63%)
Age 60.5 (range 37–78) 51 (range 37–78) 62 (range 44–76)
Gender, n (%)
Male 41 (77) 15 (79) 26 (79)
Female 11 (23) 4 (21) 7 (21)
MSKCC prognostic risk, n (%)
Intermediate 35 (66) 18 (95) 17 (52)
Poor 17 (33) 1 (5) 16 (48)
Number of metastatic sites, n (%)
00 0 0
1 15 (29) 4 (21) 11 (33)
2 17 (33) 6 (32) 11 (33)
3+ 20 (38) 9 (47) 11 (33)
Sites of metastatic disease on CT, n (%)
Lung 46 (88) 18 (95) 28 (84)
Bone 16 (31) 3 (15) 13 (33)
Lymph node 26 (50) 9 (47) 17 (52)
Liver 7 (13) 3 (15) 4 (12)
Other 12 (27) 4 (21) 8 (24)
Primary tumor size [longest
diameter (median in cm)]
9.45 (4.2–23.2) 10.3 (6.8–23.2) 9.9 (4.2–18.7)
Histology prior to surgery, n (%)
Clear cell 52 19 33
Other 0 0 0
CT, computed tomography scan; MSKCC, Memorial Sloan Kettering Cancer Center.
Figure 1. Progression-free survival curves. Some patients were not
included: (A) rapid PD/death (n = 2). Patients changed to sorafenib
(n = 1). (B) Bone metastasis only (n = 3) rapid PD/death (n = 3). Patients
changed to sorafenib (n = 1).
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patient population, design and end points. Although they were
not designed to be assessed together, combining them allows
more robust and powerful data in this setting. This is
particularly important to identify the optimal period of
sunitinib before surgery and time off drug pre-surgery, which
will help guide the randomised study which is due to start later
this year. Results showed that this approach is surgically safe
and promising in terms of efﬁcacy, with the majority (73%)
obtaining a clinical beneﬁt (stable disease, partial response and
complete response) and PFS being in line with that available for
intermediate-risk and poor-risk MSKCC disease treated with
sunitinib in mCRC [2, 10].
One of the challenges in this area surrounds trial design. These
trials were among the ﬁrst in the ﬁeld and other end points such
as PFS may have been preferential. This is underlined by the lack
of RECIST response rates in the primary tumour, which is in line
with the retrospective reports in this area [11–15], and in
contrast to the higher response rates in the metastatic sites
(Figure 2A and B). Despite this lack of responses in the primary
tumour, the majority of patients obtained some tumour
shrinkage and none became inoperable, which is reassuring.
There are other potential advantages of this upfront approach
despite the lack of primary response rates. This approach
speciﬁcally allows patients with a high metastatic burden and/or
MSKCC poor-risk disease to start sunitinib early with the hope of
identifying those who beneﬁt from treatment and subsequent
surgery, while sparing those with primary refractory disease
a nephrectomy. Table 3 and the multivariate analysis showed that
patients with poor-risk disease had impressive response and PFS
rates and did not have a signiﬁcantly worse outcome than the
intermediate group. This is reassuring for this group of patients,
where outcome remains poor [2, 10]. Temsirolimus has more
robust randomised data than sunitinib in the poor-risk population
[5]. However, sunitinib is widely used and recommend here
[10, 17]. There are currently no prospective data reporting the
effect of mTOR inhibitors in this upfront setting and retrospective
analysis in the poor-risk population failed to demonstrate a clear
advantage for nephrectomy with temsirolimus [5]. This questions
the role of nephrectomy here; however, prospective randomised
trials are required to obtain quality data. Temsirolimus was not
available in either country during the period of the trial and was
therefore not offered to patients.
There were also a number of patients who declined or were
not deemed ﬁt enough for nephrectomy, these patients were
beneﬁting from sunitinib and it was felt that the risks of
interrupting treatment and surgery outweighed the beneﬁts.
Without randomised data, it is not possible to determine
Table 2. Clinical and radiological features before and during therapy
Overall After 2 cycles of sunitinib After 3 cycles of sunitinib Intermediate-risk disease Poor-risk disease
n 52 19 33 35 17
Overall response (RECIST) at the time of surgery, n (%)
PR 5 (10) 2 (11) 3 (9) 4 (11) 1 (6)
SD 33 (63) 13 (68) 20 (61) 23 (66) 10 (58)
PD 12 (23) 4 (21) 8 (24) 7 (20) 5 (29)
Not evaluable
a 2 (4) 0 (0) 2 (6) 1 (3) 1 (6)
Response of renal tumour (RECIST) at the time of surgery, n (%)
PR 3 (4) 1 (5) 2 (6) 3 (9) 0 (0)
SD 46 (94) 16 (95) 30 (90) 30 (88) 16 (94)
PD 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Not evaluable 3 (2) 1 (0) 2 (3) 2 (3) 1 (6)
Median shrinkage of primary
tumour (%)
12 % (+ 8t o235) 11% (+ 1t o228) 12% (+ 6t o235) 13% (+ 8t o235) 10% (+6t o 228)
Response in metastatic sites (RECIST), n (%)
PR 14 (27) 5 (26) 9 (28) 9 (23) 5 (29)
SD 21 (40) 10 (53) 11 (33) 16 (20) 5 (29)
Tumor growth/PD 12 (22) 4 (21) 8 (24) 7 (20) 5 (29)
Not evaluable
b 5 (11) 0 (0) 5 (15) 3 (9) 2 (12)
Median progression-free
survival (months) with
95% CIs
8 months (6–15) 7 months (5–19) 8 months (6–15) 10 months (6–NA) 7 months (6–NA)
Cause of death, n (%)
Total 22 (46) 8 (41) 14 (42) 12 (34) 10 (58)
Renal cancer 18 (34) 7 (36) 11 (33) 9 (26) 9 (52)
Surgery related 1 (2) 0 (0) 1 (3) 1 (3) 0 (0)
Other
c 3 (6) 1 (5) 2 (6) 2 (6) 1 (6)
aStopped sunitinib and non-cancer-related death before assessment.
bPatients with bone only as a site of metastatic were not evaluable in terms of size of tumour reduction (n = 3). These data also include two non-assessable
patients (infection death and changed therapy).
CI, conﬁdence interval; NA, not achieved; PD, progression of disease; PR, partial response; SD, stable disease.
cEuthanasia/suicide (two) and infection.
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However, it does appear to have some potential advantages.
Nephrectomy occurred in 37 (70%) of the patients. Overall,
the complication rate, surgical time, duration in hospital and
blood loss were in line with untreated nephrectomies in mCRC
[8]. Indeed, in recent retrospective series describing upfront
nephrectomy, peri-operative mortality occurred in 6% [18].
Thus, nephrectomy in this population is associated with
signiﬁcant risks irrespective of its timing.
Delayed wound healing, which has been highlighted as a
potential concern by retrospective series, and other angiogenic
targeted therapies in this area (bevacizumab is associated with
a 20% incidence [12]) occurred in ﬁve patients (13%).
Fibrosis was a prominent feature during nephrectomy after
three cycles of therapy but not two. This may related to the length
of exposure to sunitinib and requires further investigation.
A concern with this upfront approach is the potential for
rebound tumour growth during the treatment interruption for
nephrectomy [19]. In this study, 25% of patients experience
progression of disease in the short time off treatment after the
nephrectomy. Subsequent stabilisation did occur (71%) after
the drug was reintroduced and two patients had a response by
RECIST criteria at this point, but numbers were small. It is
unknown what effect this progression has on overall survival,
which can be only addressed in the randomised study.
However, progression rates of 30% occur after nephrectomy in
Figure 2. Percentage change of the tumours with sunitinib (A) primary tumour (measures the longest diameter of the primary tumour) (B) metastatic site
[measures only the combined metastatic sites (RECIST v1.1)]
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these results in context [18]. This ﬁgure of 30% could
potentially be used as a benchmark of safety in this area. It is
unknown whether this progression is a consequence of growth
factor release and compromised immunity following
nephrectomy, rebound after withdrawal of sunitinib or
a combination of both. This important issue has implications
for individuals stopping sunitinib for signiﬁcant periods of
time and requires further evaluation, especially in light of the
supportive preclinical data in this area [19].
Speciﬁc differences in the design of the two studies allow us to
compare two versus three cycles of upfront therapy and whether
1-day off drug was adequate to avoid surgical complications.
Results showed that there were no speciﬁc differences between
two or three cycles of treatment, although a lower proportion of
patients who received three cycles had surgery, and at surgery,
Table 3. Surgical data for patients receiving nephrectomy after upfront sunitinib
Total 1-day off sunitinib
pre-surgery
14-days off sunitinib
pre-surgery
Nephrectomy data
Total 37 16 21
Open, n (%) 31 (84) 15 (94) 16 (76)
Laparoscopic, n (%) 4 (11) 0 (0) 4 (25)
Laparoscopic converted to open, n (%) 2 (5) 1 (7) 1 (6)
Reason for no nephrectomy
Patient choice, n (%) 2 (5) 0 (0) 2 (10)
PD of systemic disease, n (%) 9 (24) 3 (19) 6 (29)
PD of renal tumour, n (%) 0 (0) 0 (0) 0 (0)
Surgically unﬁt, n (%) 2 (5) 0 (0) 2 (10)
Other, n (%)
a 2 (5) 0 (0) 2 (10)
Surgical outcome
Blood loss (ml) 725 (90–4200) 635 (80–3000) 775 (90–4700)
Surgical time (min) 189 (70–420) 180 (80–230) 195 (70–420)
Duration in hospital (days) 8 (4–36) 8 (7–17) 7 (4–36)
T stage at nephrectomy, n (%)
T1 1 (3) 0 (0) 1 (6)
T2 2 (5) 0 (0) 2 (10)
T3a 26 (70) 13 (80) 13 (62)
T3b 4 (11) 1 (7) 3 (14)
T4 4 (11) 2 (13) 2 (10)
Necrosis at surgery, n (%)
<25% 13 (35) 7 (44) 6 (29)
25–50% 6 (16) 2 (13) 4 (19)
>50 18 (49) 7 (44) 11 (69)
Grade at surgery, n (%)
10 0 0
2 16 (43) 6 (37) 10 (48)
3 17 (46) 9 (56) 8 (38)
4 4 (11) 1 (7) 3 (14)
Surgical complications
b(Clavien–Dindo classiﬁcation), n (%)
0 27 (73) 12 (75) 15 (70)
I 6 (16) 4 (25) 2 (10)
II 0 (0) 0 (0) 0 (0)
III 1 (3) 0 (0) 1 (5)
IV 2 (5) 0 (0) 2 (10)
V 1 (3) 0 (0) 1 (5)
Median time from surgery to restarting sunitinib therapy (days) 21 (range 14–82) 24.5 (range 21–49) 16 (range 21–82)
Median time off sunitinib due to surgery (days) 28 (range 22–96) 26 (range 22–51) 28 (range 26–96)
Effect of surgery on creatinine (median values)
Before nephrectomy 78 (57–135) 88 (57–103) 75 (64–135)
After nephrectomy 109 (69–221
c)* 110 (83–157) 108 (69–221
c)
aOne patients died of infection and the other stopped sunitinib and refused surgery after 4 weeks of therapy.
bI = delayed wound healing (X2) and oedema, II = none, III = bleeding, IV = renal failure and hypotension and V = respiratory failure post o.p.
cOne dialysis dependant.
*P > 0.05.
PD, progression of disease.
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subjective ﬁnding may be due to the higher percentage of poor-
risk patients or the more prolonged time on therapy in study B.
Importantly, the 1-day treatment gap before surgery appears safe
which is reassuring, as this reduces the potential time off therapy.
It is not clear from this work whether nephrectomy should be
carried out in those patients with initial progression of disease
to facilitate further response to treatment. At ﬁrst glance,
approach appears counterintuitive, in that patients with
aggressive sunitinib-resistant disease are likely to experience
further systemic progression and subsequent deterioration
during the surgery-related treatment breaks. This could
potentially be the focus of work in the future.
The number of metastatic sites was the only signiﬁcant factor
to predict PFS in multivariate analysis. Previous work with
bevacizumab in this setting suggested that the presence of
widespread disease is associated with a poor outcome here [12].
This underlines the point that there are likely to be subgroups
of patients who do not beneﬁt from nephrectomy, which is
being addressed prospectively.
Although the two studies were remarkably similar, they were
not initially designed with the intention of combining the data,
which is a shortcoming of this work. However, central meta-
analysis of all aspects of the studies was carried out to reduce
potential bias. Both the studies were a prelude to the randomised
trial, investigating interval nephrectomy to give insight into the
safety and potential advantages of this approach. Together, they
demonstrate that either two or three cycles of sunitinib before
surgery is surgically safe and that only 1 day off treatment before
surgery is optimal. This approach appears attractive, especially
for patients with a large tumour burden and/or poor-risk
disease. However, the results of the randomised trial will be
required before it can be determined if it is beneﬁcial.
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